Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection

Core Insights - Quanterix Corporation has submitted a 510(k) premarket notification to the U.S. FDA for a multi-analyte algorithmic blood test for Alzheimer's disease, marking a significant milestone in the company's mission to enhance diagnostic capabilities in healthcare [1] Company Summary - Quanterix Corporation is focused on transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, emphasizing the importance of non-invasive and high-performance diagnostic solutions [1]